Redoxis provides validated mouse models for Parkinson's disease (PD). PD is a progressive long-term neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta projecting to the striatum along the nigro-striatal pathway. The striatal dopamine depletion causes the typical motor symptoms of PD like bradykinesia, tremor, rigidity and postural abnormalities. Another key pathological feature of PD is the presence of intracellular protein inclusions containing alpha-synuclein in many neuronal cells within regions affected by the neurodegenerative process. Alpha-synuclein protein aggregates become toxic when clustered together forming insoluble complex structures.
Redoxis provides different and complementary mouse models of PD, one of which is the unilateral intrastriatal lesion with the 6-Hydroxydopamine (6-OHDA) toxin to mimic disease hallmark. The use of toxin-mediated models like the 6-OHDA has been widely used in rodent models of Parkinson’s disease as it can reliably reproduce the selective dopaminergic loss. Other models, like transgenic PD models or AAV vector mediated models can be set up on demand to accommodate research requirements.
Mice with the 6-OHDA lesions are widely used as reliable model for understanding the mechanisms underlying parkinsonian symptoms, since it recapitulates the changes in basal ganglia circuitry and pharmacology observed in parkinsonian patients.